SCHEMBL17149778

SCHEMBL17149778

O=C(Nc1cccc2ncccc12)c1cc2cc(F)ccc2[nH]1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.61
▸ CYP3A4 P08684 1/20 0.61
▸ HDAC6 Q9UBN7 1/20 0.53
▸ MEN1 O00255 4/20 0.52
▸ KMT2A Q03164 4/20 0.52
▸ PABPC1 P11940 3/20 0.52
▸ EIF4H Q15056 3/20 0.52
▸ L3MBTL1 Q9Y468 3/20 0.52
▸ MAPT P10636 2/20 0.52
▸ RXFP1 Q9HBX9 2/20 0.52
▸ TP53 P04637 1/20 0.52
▸ POLB P06746 1/20 0.52
▸ CLK1 P49759 1/20 0.47
▸ GPER1 Q99527 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20825839 0.92 NR4A1 (0.52) CYP1A2CYP3A4MEN1KMT2AMAPT
SCHEMBL17149708 0.91 CYP1A2 (0.61) CYP1A2CYP3A4HDAC6MEN1KMT2A
SCHEMBL17149915 0.84 FLT3 (0.58) CYP1A2CYP3A4MEN1KMT2AMAPT
SCHEMBL17149795 0.83 MEN1 (0.50) MEN1KMT2AMAPTRXFP1TP53
SCHEMBL28144771 0.83 RXFP1 (0.57) MEN1KMT2AMAPTRXFP1TP53
SCHEMBL17149668 0.79 NPC1 (0.67) CYP1A2CYP3A4MEN1KMT2ARXFP1
SCHEMBL17149773 0.78 RECQL (0.55) HDAC6MEN1KMT2APABPC1EIF4H
SCHEMBL27336654 0.78 FLT3 (0.58) MEN1KMT2AMAPTRXFP1TP53
SCHEMBL2760116 0.77 FLT3 (0.54) CYP1A2MEN1KMT2AMAPTRXFP1
SCHEMBL2735816 0.77 FLT3 (0.57) MEN1KMT2AMAPTRXFP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10858319-B2 Indole derivatives for use in medicine IOMET PHARMA LTD. (GB) 2020-12-08 — — US disclosed
US-10167257-B2 Indole derivatives for use in medicine IOMET PHARMA LTD. (GB) 2019-01-01 — — US disclosed
US-20170107178-A1 INDOLE DERIVATIVES FOR USE IN MEDICINE IOMET PHARMA LTD. (GB) 2017-04-20 — — US disclosed
US-20170107178-A1 INDOLE DERIVATIVES FOR USE IN MEDICINE IOMET PHARMA LTD. (GB) 2017-04-20 — — US disclosed
WO-2015150097-A1 INDOLE DERIVATIVES FOR USE IN MEDICINE IOMET PHARMA LTD (GB) 2015-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10858319-B2 Indole derivatives for use in medicine IDO1, IDO2, TDO2 CYP1A2 67/4885CYP3A4 42/4885HDAC6 1422/4885
US-10167257-B2 Indole derivatives for use in medicine IDO1, IDO2, TDO2 CYP1A2 64/4885CYP3A4 40/4885HDAC6 1368/4885
US-20170107178-A1 INDOLE DERIVATIVES FOR USE IN MEDICINE IDO1, IDO2, TDO2 CYP1A2 64/4885CYP3A4 40/4885HDAC6 1368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback